Rani Therapeutics (RANI) Q4 2025 earnings summary

Executive summary

• Achieved significant progress in advancing and validating the RaniPill platform across multiple therapeutic modalities in 2025 and entered 2026 with the initiation of Phase 1 study for RT-114, an oral GLP-1/GLP-2 dual agonist.

• Entered a major collaboration and licensing agreement with Chugai Pharmaceutical, potentially worth up to $1.1 billion, focused on oral delivery of biologics.

• Strengthened financial position with an oversubscribed $60.3 million private placement, reducing debt and extending cash runway into Q4 2027.

• Presented robust preclinical data for oral delivery of semaglutide and RT-114, showing bioequivalence to injectable forms.

• Appointed new board members and promoted a new Chief Technical Officer.

Financial highlights

• Cash, cash equivalents, and marketable securities totaled $49.7 million at year-end 2025, up from $27.6 million in 2024.

• Contract revenue for 2025 was $1.6 million, mainly from the Chugai agreement.

• Research and development expenses decreased to $20.2 million in 2025 from $26.7 million in 2024 due to cost containment.

• General and administrative expenses fell to $19.7 million in 2025 from $23.9 million in 2024.

• Net loss for 2025 was $41.0 million, an improvement from $56.6 million in 2024.

Outlook and guidance

• Projected cash runway extends into Q4 2027, supported by current cash and expected milestone payments.

• R&D expenses expected to increase as select programs resume and platform development advances.

• Focus remains on advancing RT-114 in the clinic and expanding strategic partnerships.